Using state-of-the-art equipment and the newly developed iPSC stem cell resource, scientists are investigating the behaviour of industry-developed drugs in new contexts.
The Wade-Martins group (University of Oxford) has set up successful collaborative projects with industry. This has enabled screening of large compound libraries using complex 'disease in a dish' models for various neurodegenerative diseases derived from reprogrammed iPSCs.
Professor Richard Wade-Martins' group at the University of Oxford:
For more information contact Dr Sarah Pearce (email@example.com).